Neonatal manifestations of maternal phencyclidine exposure by Golden, Nancy L. et al.
Golden et al, Maternal phencyclidine use and neonatal manifestations 185
J. Perinat. Med.
15 (1987) 185
Neonatal manifestations of maternal phencyclidine exposure
Nancy L.Golden, Betty R. Kuhnert, Robert J. Sokol, Susan Martier, and Thomas
Williams
Department of Pediatrics and Reproductive Biology, Cleveland Metropolitan
General Hospital/Case Western Reserve University School of Medicine, Cleve-
land, Ohio, U.S.A.
1 Introduction
Phencyclidine (angel dust) is a drug frequently
abused by adolescents and young adults. For
example, a New York State study of secondary
school students indicated that 15.5% of stu-
dents (276,000) had used phencyclidine [9]. Al-
though originally developed as a short acting
anesthetic, phencyclidine's sedative and halluci-
nogenic effects have made it a popular drug of
abuse among young people of childbearing age
[11]. The use of phencyclidine by pregnant
women is of concern since phencyclidine has
been shown to cross the placenta and to reach
the fetus [13].
There have been several reports in which phen-
cyclidine exposure during gestation has been
associated with adverse effects on the fetus.
In one report, two neonates exposed in utero
demonstrated a classic withdrawal syndrome
[13]. They were irritable, hypertonic, jittery, and
had diarrhea and vomiting for several days
postpartum. A second report described neuro-
logic and anatomic abnormalities in one infant
whose mother had used large amounts of phen-
cyclidine throughout pregnancy [2]. This infant
had an abnormal neurologic examination and
abnormal behavior in the neonatal period; he
was jittery, irritable, hypertonic, unable to track
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visually, and a poor feeder. Furthermore, his
appearance was unusual; he had a triangularly
shaped face, eyes with an antimongoloid slant,
and a pointed chin. At the age of five he had
spastic quadriparesis and was severely mentally
retarded.
Given the reported frequency of phencyclidine
use, the fact that phencyclidine crosses the pla-
centa, and the possibility that intrauterine ex-
posure to phencyclidine may be harmful to the
fetus, we undertook a large prospective study to
describe the extent of phencyclidine use during
pregnancy and the characteristics of the user
population [4]. The results of consecutive
screening of more than 2,000 pregnant women
between 1981 and 1982 showed that 7.3 percent
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gave a verbal history of phencyclidine use but
only 0.8 percent could be confirmed as current
users by maternal urine screening [4], The pur-
pose of the present study was to describe the
physical characteristics, neurologic findings, be-
havior, and neonatal clinical course of the in-
fants of these women, and to compare them
with a group of matched control infants.
2 Methods
All women attending the prenatal clinics affili-
ated with Cleveland Metropolitan General
Hospital from June, 1981 through October,
1982 were questioned on their initial visit about
their drug, tobacco, and alcohol use. Trained
screeners took substance abuse histories [4] and
administered Michigan Alcoholism Screening
Tests [10].
Study patients were defined as those who gave
a verbal history of phencyclidine use during
pregnancy and/or positive urine tests. Potential
control patients were defined as those who did
not have a history of phencyclidine use during
pregnancy and whose urine tests were negative
for phencyclidine. For this study, control
patients were matched to study patients on
maternal date of recruitment, age, ethnicity,
weight, parity, weeks gestation at registration,
and tobacco smoking behavior.
All patients' urines were initially screened for
phencyclidine using the Enzyme Mediated Im-
munoassay Technique (EMIT) [1]. Specimens
were initially defined as "positive" if the EMIT
reading was ten units above the negative cali-
brator. The presence of phencyclidine was sub-
sequently verified by gas chromatography —
mass spectrometry, using previously reported
methodology [7]. Urines from study patients
and any controls thought to be at risk for drug
abuse were retested at each visit. Most of the
patients had their urines tested 4 — 5 times prior
to delivery. Furthermore, study patients and
neonates had urine and blood analyses during
the intrapartum and postpartum period. All
bloods were negative. The results of the phar-
macological analyses have been reported separ-
ately [8]. Control patients' urines were also re-
tested during the intrapartum period.
Table I. Neonatal outcome variables.
Anatomy
Widely patent sutures
Slanted eye shape
Narrow mandibular angle
Decreased joint mobility
Flexed joints
Neurologic function
Abnormal movement
Hypertonia
Hypotonia
Tremors
Decreased vision
Decreased hearing
Asymmetrical facial movement
Abnormal extra ocular movements
Decreased pupil reactivity
Miotic pupil position
Nystagmus-vertical
Nystagmus-horizontal
Increased ankle reflex
Increased knee reflex
Increased brachial reflex
Depressed suck reflex
Depressed root reflex
Depressed grasp reflex
Abnormal galant reflex
Abnormal moro reflex
Abnormal step reflex
Behavior
Poor tracking
Decreased attention
Mood (irritability)
Poor feeding
High pitched cry
Physiologic function
Heart rate - < 90 >
Respiratory rate — <
Sepsis
Jaundice
Hypoglycemia
Hypocalcemia
Anemia
Respiratory distress
Other
160
20 > 60
Growth
Height - < 10% > 90%
Weight - < 10% > 90%
Head circumference —
< 10% > 90%
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Study and control neonates were evaluated mid
feeding between 24 and 72 hours of age by a
single examiner blind to the maternal history.
This examiner is a certified pediatric nurse prac-
titioner who is also a certified Brazelton exam-
iner with additional experience screening Fetal
Alcohol Syndrome infants [3]. Growth para-
meters, physical characteristics, neurologic
findings, and behavior were documented ac-
cording to a format based on previous descrip-
tions of phencyclidine exposed infants (table I)
[2, 13].
The data were analyzed in the following ways:
First, descriptive statistics and paired t tests
were used to compare study and control popu-
lations in regard to maternal age, race, parity,
smoking behavior, and number of drugs used.
Next, a hierarchial analysis was used to exam-
ine the relationship between drug use and neon-
atal outcome. First, paired t tests were used to
compare the total number of abnormal findings
between the study and control infants and the
frequency of abnormalities were plotted on his-
tograms. Next, stepwise multiple regression
techniques with nonforced variables were used
to determine relationships between neonatal
outcome and the seven classes of maternally
abused substances (phencyclidine, narcotics,
barbiturates, cocaine, marijuana, glue, and al-
cohol). Then, chi square tests were used to
determine which of the dichotomous outcome
variables were significantly different in study
and control neonates. Finally, stepwise dis-
criminant function analysis was used to relate
specific outcome variable to phencyclidine use.
A probability level p < 0.05 was accepted as
significant.
3 Results
A total of 2,327 pregnant women were screened
for phencyclidine use early in pregnancy. A
verbal history of phencyclidine use during preg-
nancy was reported by 149 (6.4%) and current
use was reported and/or documented in 23
(1%). Data collection was completed for 94
study patients, 14 of whom were verified users,
and 94 matched controls. Table II summarizes
Table II. Entry of patients into neonatal PCP study.
Parameter Number
Women screened 2347
Positive responders 172
Historical use 149
Confirmed use 23
Positive responders lost to follow-up 78
Remaining study patients 94
Historical use 80
Confirmed use 14
the entry of patients into the study. Most
patients lost to follow-up were lost due to deliv-
ery at another hospital, delivery at times when
examinations could not be obtained or refusal
participate. The demographic characteristics of
this population has been described in depth [4]
and previous analysis indicated that there were
no significant demographic differences between
the patients studied and those lost to follow-
up.
Table III shows that study and control groups
differed significantly only in the mean number
of drugs used. This was true both within the
total study sample and the subset of confirmed
users. Both study and control patients most
frequently abused marijuana, cocaine, barbitu-
ates, alcohol and glue in that order. Matching
criteria were effective as both groups were
found to be similar in maternal age, race, par-
ity, and smoking behavior. Furthermore, other
maternal characteristics, for which patients
were not matched, were also similar in the study
and control groups. Maternal education and
socioeconomic status were not statistically dif-
ferent between study and control groups.
Patients were also similar in terms of medical
obstetric risk. Antenatal risk scores (Hobel)
[12] were similar after adjustment for substance
abuse. Furthermore, the infants were all at term
and similar in regards to intrapartum risk and
apgar scores.
A significantly increased number of abnormal
findings in neonates was associated with ma-
ternal phencyclidine exposure (table IV). There
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Table III. Comparison of study and control mothers.
Historical and confirmed (94 pairs) Confirmed users (14 pairs)
Studya Control
Age
Mean ± SD 20.78 ± 3.06 21.11 ± 3.87
Race
White 70 70
Appalachian 7 7
Hispanic 2 2
Black 14 14
Parity
Mean ± SD 0.91 ± 0.95 0.99 ± 1.04
Education (Years) 10.77 ± 1.69 9.13 ± 1.54
Socioeconomic status
(Hollingshead) 4.91 ± 0.32 4.90 ± 0.39
Religion
Catholic 52 56
Protestant 26 24
Other 15 13
Smoking
Yes 77 77
No 17 17
Number of classes of
drugs used
Total number 133 58
Mean + SD 1.41 ± 1.15 0.64 ± 0.80
Antenatal risk score0 20.94 ±11.88 15.89 ± 8.88
a
 80 with history of use and 14 verified present users
b
 14 verified users
c
 Modified Hobel
Table IV. Abnormal findings in neonates of phencycli-
dine exposed women.
Study Control
(N = 94) (N = 94)
Total number of
abnormal findings 477 392
Mean ± SD 5.07 ± 2.93 4.17 ± 2.65
Significance* p < 0.01
* Paired t test
were significantly more abnormalities in both
the sample which included all users, and in the
subset of confirmed users. In the latter group,
Signi- Studyb Control Signi-
ficance ficance
NS 20.42 ± 2.38 19.86 ± 2.77 NS
NS 7 7 NS
NS 2 2 NS
NS - - NS
NS 5 5 NS
NS 0.86 ± 0.86 1.00 ± 0.88 NS
NS 10.57 ± 1.40 10.14 + 1.51 NS
NS 4.93 ± 0.27 4.93 ± 0.36 NS
NS 11 10 NS
NS 3 4 NS
NS 0 0 NS
NS 12 12 NS
NS 2 2 NS
p < 0.001 37 4 p < 0.00l
2.64 ± 1.39 0.31 ± 0.63
p < 0.001 21.71 ± 17.08 13.93 ± 11.33 NS
the study infants averaged 5.8 + 3.3 abnormal-
ities and the control group averaged 3.5 + 2.4
abnormalities (p < 0.02). While the means were
different, the histograms (figure 1) of study and
control patients, show that the distributions of
abnormalities were similar in each group.
Many of the study patients were multiple drug
users. However, stepwise multiple regression
techniques showed that the number of abnor-
malities was related to phencyclidine use and
not other drugs. Phencyclidine was the only
substance of the seven classes of substances
abused by the patients which accounted for a
significant portion of the variance related to
J. Perinat. Med. 15 (1987)
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Figure 1. Number of abnormalities seen in infants of
phencyclidine exposed women (·) and infants of con-
trols (χ) .
the number of abnormal findings (F = 4.38;
df = 1,138; ρ < 0.05). Nevertheless, drug inter-
actions cannot be ruled out. There were no
opiate users in the study sample.
Abnormal neurological and behavioral findings
were associated with maternal phencyclidine
exposure (table V). Those found significantly
more often in the study group included poor
attention, hypertonic ankle reflexes, and de-
pressed neonatal reflexes — grasp and rooting.
The abnormal grasp reflex was the only reflex
significantly related to phencyclidine use with
stepwise discriminant function analysis
(F = 8.38; df = 1,174; ρ < 0.01). No signifi-
cant relationships were found between abnor-
mal anatomic findings and maternal phencycli-
dine use.
Table V. Specific abnormal findings more frequent in
study infants.
Abnormal findings Signi-
ficance*
Decreased attention 0.01
Depressed neonatal reflexes
Grasp 0.01
Root 0.03
Hyperactive deep tendon reflexes ankle 0.05
* Pearson's χ2
4 Discussion
The results of this study of 188 infants suggest
that infants born to women with a history of
phencyclidine use during pregnancy have more
abnormal neurological and behavioral findings
at birth than control infants. These abnormali-
ties are related to phencyclidine use and not to
other drug use. However, interactions with
other drugs cannot be ruled out. No anatomical
abnormalities were detected, but the sample
size may need to be much larger to see these
abnormalities.
Women with a verbal history of phencyclidine
use, as well as those with chemically confirmed
use during pregnancy, were included in the
study group for two reasons: First, phencycli-
dine use could be confirmed in only a small
percentage of the population. This was prob-
ably due to infrequent urine testing [4]. There-
fore, the frequency of phencyclidine use (which
exceeds 15% in some populations [9]) would
almost certainly be underestimated and many
users would have been missed if only the con-
firmed users had been studied. The decision to
include historical and confirmed users as study
patients appears justified since the numbers of
abnormal findings were similar in these two
groups.
The results of this study do not completely
agree with what has previously been reported.
These findings are similar to those of a report
which described an infant exposed to phencycli-
dine in utero with lethargy, inability to track
visually, hypertonicity, and poor feeding [2].
However, the results of the present study are
different in that structural abnormalities were
not found. Thus, this study suggests that phen-
cyclidine is not an anatomic teratogen but does
not confirm this. A larger sample size may be
needed to see anatomical abnormalities. Fur-
thermore, the possibility exists that study in-
fants were not exposed to phencyclidine at the
time of organ formation, or that exposure was
of insufficient amount or duration to cause
structural defects such as those previously re-
ported [2]. Moreover, the earlier report involved
an infant also exposed simultaneously to very
J. Perinat. Med. 15 (1987)
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high amounts of marijuana throughout gesta-
tion.
Even though phencyclidine users are almost
always multiple drug abusers [4], this study
demonstrated statistically significant effects on
the fetus only from phencyclidine exposure.
However, previous studies have suggested a
relationship between gestational exposure to
barbiturates [6], marijuana [2, 5], and alcohol
[13] and an adverse fetal outcome. In addition,
past studies have shown that narcotic exposure
can have severe effects on the neonates [14].
Since none of the patients in this study were
narcotics users, this study cannot address the
issue of neonatal effects due to combined phen-
cyclidine and narcotic use.
The results of this study suggest that long-term
follow-up of these infants would be worthwhile.
While it is unlikely that the neonatal findings
would directly correlate with long-term find-
ings, one could speculate that these children
may be at increased risk of minor neurologic
abnormalities and/or learning difficulties.
Our previous study indicated that phencyclidine
use during pregnancy was widespread [4]. This
study suggests that exposure of the fetus to
phencyclidine can result in abnormal neonatal
neurologic findings and behavior. Future stud-
ies must determine the long-term effects of
exposing the fetus to phencyclidine.
Summary
The purpose of this study was to determine the effects
of maternal phencyclidine use on the fetus. Ninety-four
neonates with maternal phencyclidine exposure were
compared with 94 controls. Maternal phencyclidine use
was assessed by questionnaire and repeated urine testing.
Mothers of study and control patients were matched
for demographic characteristics. Infants were assessed
between 24—72 hours postnatally by a single examiner
blind to the maternal history. The results showed that
study infants had a mean of 5.02 + 2.93 abnormalities
while controls had a mean of 4.13 ± 2.65 abnormalities
(p < 0.01). Furthermore, study infants were more likely
than controls to have poor attention, hypertonia, and
depressed neonatal reflexes (p < 0.05). The contribution
of seven drug classes to the total number of abnormali-
ties was assessed using stepwise multiple regression. Only
phencyclidine accounted for a significant proportion of
the variance (f = 4.38; p < 0.05). The results of this
study suggest that maternal phencyclidine use may lead
to abnormal neonatal neurologic findings and behavior.
Keywords: Fetus, newborn infant, pregnancy, prenatal exposure delayed effects, phencyclidine, phencyclidine
abuse.
Zusammenfassung
Manifestationen einer mütterlichen Phenzyklidineinnahme
beim Neugeborenen
In der vorliegenden Studie wurden die Auswirkungen
einer mütterlichen Phenzyklidineinnahme auf den Feten
untersucht. 94 Neugeborene von Müttern, die Phenzy-
klidin eingenommen hatten, wurden verglichen mit 94
Kontrollkindern. Der Phenzyklidinabusus wurde über
Fragebögen und wiederholte Urintests erfaßt. Frauen
aus der Phenzyklidingruppe und Frauen der Kontroll-
gruppe wurden nach demographischen Parametern ein-
ander zugeordnet. Die Kinder wurden von einer einzigen
Person, die die mütterliche Vorgeschichte nicht kannte,
innerhalb von 24 — 72 Stunden post partum untersucht.
Kinder aus der Phenzyklidingruppe zeigten im Mittel
5.02 + 2.93 auffallige Befunde, Kinder aus der Kontroll-
gruppe dagegen 4.13 ± 2.65 (p < 0.01). Darüber hinaus
fielen bei den Kindern der Phenzyklidingruppe im Ver-
gleich zur Kontrollgruppe eine verminderte Reaktions-
bereitschaft, ein erhöhter Tonus sowie herabgesetzte
neonatale Reflexe auf (p < 0.05). Durch eine multiple
Regressionsanalyse wurde für 7 Medikamentengruppen
ermittelt, wie häufig auffallige Befunde bei den Kindern
auftraten. Nur für Phenzyklidin konnte ein signifikanter
Anteil an der Varianz berechnet werden (f = 4.38;
p < 0.05). Die Ergebnisse zeigen, daß eine mütterliche
Phenzyklidineinnahme zu auffalligen neurologischen Be-
funden und Verhaltensmustern beim Neugeborenen füh-
ren kann.
Schlüsselwörter: Fetus, Neugeborenes, Phenzyklidin, Phenzyklidinabusus, pränatale Exposition und Manifestation
beim Kind, Schwangerschaft.
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Resume
Manifestations neo-natales de la prise maternelle de phen-
cyclidine
Le but de cette etude a etc de determiner les effets de la
prise maternelle de phencyclidine sur le foetus. On a
compare quatre vingt quatorze nouveaux-nes dont la
mere avait pris de la phencyclidine avec 94 controles.
On a determine la prise maternelle de phencyclidine a
l'aide de questionnaires et par des analyses urinaires
repetees. Les meres de I'etude et les patientes temoins
ont etc appariees selon les caracteres demographiques.
Les enfants ont ete examines entre 24 et 72 heures
de vie par un seul examinateur qui ne connaissait pas
Fhistoire maternelle. Les resultats ont montre que les
enfants de I'etude presentent en moyenne 5,02 ± 2,93
anomalies tandis que les controles ont en moyenne
4,13 + 2,65 anomalies (p < 0,01).
En outre, les enfants etudies presentent plus souvent que
les temoins une attention faible, une hypertonie et des
reflexes neonataux deprimes (p < 0,05). A Taide d'une
courbe de regression multiple, on a estime le role de 7
types de medicaments face au nombre total d'anomalies.
Seule la phencyclidine entrame une variance significative
(f = 4,38; p < 0,05).
Les resultats de cette etude suggerent que la prise mater-
nelle de phencyclidine peut entrainer des anomalies de
Fexamen neurologique neonatal et des troubles du com-
portement.
Mots-cles: Abus de phencyclidine, effet ä long terme de Fexposition prenatale, foetus, grossesse, nouveau-ne,
phencyclidine.
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With advancing knowledge of the physiology of the hypothalamic-pituitary-
ovarian axis and how gonodal steroids influence cerebral neurohumors, bone
and skin metabolism, serum lipoproteins, a new approach to the management of
the perimenopausal years is now possible. The dimensions of the menopausal
syndrome may now be extended to include not only vasomotor symptoms, but
also metabolic disorders, bone loss, decreases in skin collagen, reversal of high
and low density lipoproteins, and psychogenic disturbances (menopausal
anxiety and depression, migrainoid headaches, insomnia and sexual dysfunc-
tion) that are initiated or aggravated by loss of ovarian hormones.
The text furnishes much information that is not generally known - to wit:
• estrogens and androgens diminish collagen loss of the skin,
• estrogens and progestogens not only prevent further bone decay but may
increase bone density,
• cyclic progestogens added to an estrogen regimen actually lessen the natu-
ral incidence of endometrial cancer and may add some degree of protection
against development of breast malignancy.
• non-bacterial urinary incontinence and nocturia may be partially or com-
pletely alleviated by estrogen therapy.
• androgens added to an estrogen regimen increase sexual fantasies and
desire, and facilitate the orgasmic response.
Φ the danger of myocardial infarction may be reduced greatly by estrogens
because of their beneficial effect on high density lipoproteins.
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